Search

Your search keyword '"Chan, Wah‐Kheong"' showing total 604 results

Search Constraints

Start Over You searched for: Author "Chan, Wah‐Kheong" Remove constraint Author: "Chan, Wah‐Kheong"
604 results on '"Chan, Wah‐Kheong"'

Search Results

2. A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease

3. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

4. Global burden of metabolic diseases, 1990–2021

5. Burden of disease attributable to high body mass index: an analysis of data from the Global Burden of Disease Study 2021

6. The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus

7. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease

10. An international multidisciplinary consensus statement on MAFLD and the risk of CVD

11. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

12. acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter Study

14. Validation of the Blood Test MACK-3 for the Noninvasive Diagnosis of Fibrotic Nonalcoholic Steatohepatitis: An International Study With 1924 Patients

16. A global research priority agenda to advance public health responses to fatty liver disease

17. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

21. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores

22. GS-004 Prognostic significance of a change in liver stiffness measurement by vibration-controlled transient elastography-a multicenter cohort study of 10, 920 patients with metabolic dysfunction-associated steatotic liver disease (MASLD)

23. SAT-438 Fatigue is an Important Driver of Work Productivity Loss and Impairment of Patient-Reported Outcomes (PROs) among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

24. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry

25. A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease

26. LIVERSTAT for risk stratification for patients with metabolic dysfunction‐associated fatty liver disease.

27. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study

29. Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

30. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis

32. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

33. Diagnostic accuracy of non‐invasive tests to screen for at‐risk MASH—An individual participant data meta‐analysis.

34. Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity.

37. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

38. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

39. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study

42. Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study

43. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

48. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease.

50. Prevalence of metabolic syndrome and metabolic dysfunction-associated fatty liver disease in Malaysia 2023: study protocol for a community-based nationwide cross-sectional survey

Catalog

Books, media, physical & digital resources